Filing Details
- Accession Number:
- 0001493152-24-022195
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-31 16:05:29
- Reporting Period:
- 2024-05-30
- Accepted Time:
- 2024-05-31 16:05:29
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1359931 | Protara Therapeutics Inc. | TARA | Biological Products, (No Disgnostic Substances) (2836) | 204580525 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1595855 | Opaleye Management Inc. | One Boston Place, 26Th Floor Boston MA 02108 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.001 Per Share | Disposition | 2024-05-30 | 9,230 | $2.94 | 114,520 | No | 4 | S | Indirect | By Managed account |
Common Stock, Par Value $0.001 Per Share | Disposition | 2024-05-31 | 5,824 | $2.90 | 108,696 | No | 4 | S | Indirect | By Managed account |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By Managed account |
No | 4 | S | Indirect | By Managed account |
Footnotes
- Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
- The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.90-$2.98 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
- The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.9007-$2.9011 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.